GenSight raises EUR 40M in Euronext IPO

Gene therapy company GenSight Biologics S.A. (Euronext:SIGHT) raised EUR 40 million ($44.1 million) through the

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE